162 related articles for article (PubMed ID: 27726213)
21. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
22. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
[TBL] [Abstract][Full Text] [Related]
23. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
24. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
25. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
[TBL] [Abstract][Full Text] [Related]
26. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E
Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
[TBL] [Abstract][Full Text] [Related]
28. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
29. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
30. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
31. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
Fodor FH; Weston A; Bleiweiss IJ; McCurdy LD; Walsh MM; Tartter PI; Brower ST; Eng CM
Am J Hum Genet; 1998 Jul; 63(1):45-51. PubMed ID: 9634504
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
33. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061
[TBL] [Abstract][Full Text] [Related]
34. A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of
Best AF; Tucker MA; Frone MN; Greene MH; Peters JA; Katki HA
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):293-302. PubMed ID: 30692095
[TBL] [Abstract][Full Text] [Related]
35. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
[TBL] [Abstract][Full Text] [Related]
36. Anticipation in hereditary breast cancer.
Dagan E; Gershoni-Baruch R
Clin Genet; 2002 Aug; 62(2):147-50. PubMed ID: 12220452
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
[TBL] [Abstract][Full Text] [Related]
38. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract][Full Text] [Related]
39. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
40. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]